ANABV
AnaptysBio, Inc. Common Stock When Issued
Set alert
- YTD
- -3.78%
- 1 year
- -3.78%
- Open
- 42.04
- Prev close
- 43.80
- Mkt cap
- 1.26B
- Vol
- 2.21K
- Avg vol
- 2.11K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 42.00
- High
- 43.85
- Beta
- 0.41
- Inst. own
- 0.00%
- Dividend
- 0.00
- Earnings
- May 7, 2026
Key statistics
- Market cap
- 1.26B
- Enterprise value
- 0
- Trailing P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Beta
- 0.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
Next earnings
May 7, 2026
Expected May 7, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Jun 30, 2026 | -0.96095 | — | — | — |
| Mar 3, 2026 | Mar 30, 2026 | 0.863 | 1.58 | +0.72 | +83.08% |
About AnaptysBio, Inc. Common Stock When Issued
AnaptysBio, Inc. operates as a clinical-stage biotechnology firm, primarily focused on the development of novel antibody product candidates. Its pipeline prominently features therapeutic agents such as ANB030 and Imsidolimab. The company also utilizes a proprietary SHM platform, which biologically replicates the human immune system's natural process of somatic hypermutation. This advanced technology allows for the rapid in vitro generation of a diverse array of therapeutic-grade antibodies. Established in November 2005 by founders Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon, AnaptysBio maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Website
- anaptysbio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ANABV — it syncs with the Stock Master app.